1.
Open Forum Infect Dis
; 5(10): ofy221, 2018 Oct.
Article
in English
| MEDLINE
| ID: mdl-30568974
ABSTRACT
HIV integrase mutation T97A emerges after suboptimal therapy with integrase strand transfer inhibitors (INSTIs), but the contribution of T97A to dolutegravir resistance remains uncertain. Here we report >10-fold increase in dolutegravir resistance after the single addition of T97A in 2 individuals with prior INSTI resistance receiving dolutegravir salvage therapy.